Status:
COMPLETED
Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge
Lead Sponsor:
Northwell Health
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The FDA has provided an emergency waiver for the use of non-invasive continuous glucose monitors (CGM) in hospitals, so frontline health care providers (in hospitals) can remotely monitor patients wit...
Detailed Description
In hospitalized patients diagnosed with COVID-19, diabetes mellitus is associated with a higher mortality. Patients with controlled blood glucose have a lower mortality rate than those who are uncontr...
Eligibility Criteria
Inclusion
- Participants acquired from among all non-critical care in patients who are living with Diabetes Mellitus. Because the patients will have to be instructed on the use of the CGM, this study will be limited to English speaking/reading adults (18 years of age or older), who possess the cognitive and physical ability to participate.
Exclusion
- Minors, pregnant women, and critically ill.
Key Trial Info
Start Date :
June 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT04417270
Start Date
June 12 2020
End Date
November 30 2020
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lenox Hill Hospital
New York, New York, United States, 10022